Dicerna Signs Research Collaboration and License Agreement with Kyowa Hakko Kirin
News Jan 07, 2010
Dicerna Pharmaceuticals, Inc., and Kyowa Hakko Kirin Co., Ltd. have announced that the two companies have entered into a research collaboration and license agreement for the research, development and commercialization of drug delivery systems and DsiRNA pharmaceuticals for therapeutic targets in oncology.
“We are very pleased to enter into this exciting collaboration with Kyowa Hakko Kirin,” said James C. Jenson, Ph.D., chief executive officer and co-founder of Dicerna. “This partnership is a further validation of Dicerna’s proprietary Dicer Substrate Technology platform and our unique ability to generate a greater number of more potent molecules. This collaboration provides us with the opportunity to develop novel Dicer Substrate siRNA therapies and related drug delivery systems while working with an innovative biopharmaceutical partner.”
Under the terms of the collaboration, Dicerna will receive $4 million in upfront cash payments including research funding, and up to $120 million in additional research funding, development and commercial milestones for exclusive rights to one target in the field of oncology.
According to the progress of the research collaboration, Kyowa Hakko Kirin and Dicerna may expand the scope of the collaboration by adding approximately up to ten targets under similar terms and may broaden the therapeutic focus of the partnership. Dicerna is entitled to royalty payments on sales from products for these targets. Dicerna also has an option to equally co-promote and profit-share (50:50) in the United States for the initial target.
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer’s disease – even before they show signs of confusion and memory loss, according to a new study from Washington University School of Medicine in St. Louis and the German Center for Neurodegenerative Diseases in Germany.READ MORE